Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Apple

Target

Low payout ratios and tons of cash make these stocks solid income investments that you can buy and forget about.

3 Dividend Stocks That Are Safer Investments Than AT&T

BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.

BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constructing the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.

Becton Dickinson To Build Fourth Facility In Spain To Expand Pre-Filled Drug Delivery Business

MADRID, May 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain, that will create up to 600 jobs by 2030. BD plans to begin construction of the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.

BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business

FRANKLIN LAKES, N.J., May 13, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

, a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an independent, publicly traded company (“NewCo”).

Becton Dickinson To Spin Diabetes Care Unit In 2022

Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.

Becton, Dickinson & Co. Continues to Shine

AbbVie

Aflac

Cardinal Health

Cincinnati Financial

Kimberly-Clark

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

People's United Financial

AT&T

Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however.

10 Of The Best Value Picks Among Dividend Aristocrats

Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q2

While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed “NewCo.”

Becton Dickinson To Spin-Off Diabetes Care Business: Highlights

Becton Dickinson and Co (NYSE: BDX) reported Q2 revenues of $4.91 billion, an increase of 15.4% Y/Y, slightly better than the consensus of $4.89 billion. The growth was driven by the contribution of its COVID-19 diagnostic revenues, which totaled $480 million, and strong core business growth.

BDX Q2 Earnings Top Estimates, Reports $480M COVID-19 Diagnostic Sales; Reaffirms FY21 Guidance

Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading.

Becton Dickinson beats profit expectations, plans to spin off Diabetes Care business

FRANKLIN LAKES, N.J., May 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021.

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

FRANKLIN LAKES, N.J., May 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company ("NewCo").

BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Becton, Dickinson (BDX)

FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor healthcare conferences during the month of May: The Bank of America Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m.

BD to Present at Upcoming Investor Health Care Conferences in May

FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV.

BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula

FRANKLIN LAKES, N.J., April 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021, succeeding John DeFord.

Elizabeth McCombs Appointed Chief Technology Officer at BD

ZARAGOZA, Spain and FRANKLIN LAKES, N.J., April 27, 2021 /PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ Molecular Diagnostic System can now be run on saliva specimens.

CerTest Biotec, BD Announce Addition of Saliva to the CE Marked VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ Molecular Diagnostic System

Abbott Labs

Merck

Healthcare stocks have some excellent dividend stocks among their ranks, and these three names are among the most reliable to buy. The post 3 Top Blue-Chip Healthcare Stocks With Healthy Dividends appeared first on InvestorPlace.

3 Top Blue-Chip Healthcare Stocks With Healthy Dividends

FRANKLIN LAKES, N.J., April 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States.

BD Announces FDA 510(k) Submission for BD Alaris™ System

FRANKLIN LAKES, N.J., April 23, 2021 /PRNewswire/ -- USA Track & Field (USATF) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to provide rapid COVID-19 testing for USATF athletes at Journey to Gold meets to help get USATF professional athletes back to competition safely through the use of the BD Veritor™ Plus system.

USATF Partners With BD To Provide Rapid COVID-19 Testing To Enhance Athlete Safety At Track & Field Events

Fulgent Genetics

QuidelOrtho Corp

Less COVID-19 testing means less revenue for some companies.

Which Stocks Are the Biggest Losers From Sinking COVID Testing Rates?

FRANKLIN LAKES, N.J., April 22, 2021 /PRNewswire/ -- In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming the first phase of its 2030+ sustainability goals – climate change targets.

News for Becton, Dickinson and Co. Stock (BDX)